Personal profile

Research overview

I retired from the University in 2020 and maintain an Emeritus position. From 2014-2019 I was Master and Deputy Principal, and for nine months in 2016 I was also acting Principal and Vice Chancellor. My research interests are now maintained through a University spinout company, Pneumagen, formed in 2016. This arose from having studied the structural biology of sialidases (or neuraminidases) for several decades. We engineered mutlivalent forms of carbohydrate-binding modules specific for sialic acid, a key component of the receptor used by the influenza virus, parainfluenza virus, some coronaviruses and pneumococci. In animal studies, these have shown protection against a variety of respiratory viruses, inclding influenza virus, respiratory syncytial virus and SARS-CoV-2. The lead biologic, Neumifil, is currently undergoing Phase 2 clincial studies. The company's research group is based in my old research space in BSRC.

Industrial relevance

Structure-based drug design of anti-microbials

Academic/Professional Qualification

B.Sc., Physics 1st Class; Ph.D.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being


Dive into the research topics where Garry Lindsay Taylor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or